AGC Biologics CEO Patricio Massera to Step Down After 12 Years

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced that its Chief Executive Officer (CEO), Patricio Massera, will be stepping down from his role effective June 30.

Patricio Massera joined the company in 2012, starting as General Manager of the Copenhagen site at CMC Biologics A/S. He later served as Chief Operating Officer of CMC Biologics at its Seattle headquarters. Following the acquisition of CMC Biologics by AGC Inc., which led to the formation of AGC Biologics, Mr. Massera continued in his role and was appointed CEO in 2019. He also served as an Executive Officer of the AGC Life Science Company, a division of AGC Inc.

During his tenure as CEO, Mr. Massera spearheaded several initiatives that elevated AGC Biologics' global business and brand. His work and achievements include navigating the COVID-19 pandemic, acquiring Molecular Medicine S.p.A. ("MolMed") in Milan to create AGC Biologics’ Global Cell and Gene business, and acquiring facilities in Boulder and Longmont, Colorado, to establish new large-scale commercial mammalian capacity and cell and gene services in North America. Mr. Massera also directed the company’s commitment to investing in single-use technology to ensure AGC Biologics could address the evolving needs of pharmaceutical companies using any platform process to develop new drug candidates.

Mr. Massera reflected on his time at AGC Biologics, stating, “Over the past 12 years, I have had the privilege of experiencing the most vibrant and remarkable professional position of my life. CMC Biologics, and later AGC Biologics, have provided me with countless opportunities. I have met incredible individuals driven by the desire to build a better world, all sharing the common purpose of enabling our partners to cure life-threatening diseases and bring hope to life.” He added, “During this journey, we have managed to grow the business multiple times. However, like all great stories, every book has an end. In this case, it is just a chapter that finishes. AGC Biologics has a long and brilliant journey ahead, but it is time for someone else to write the next chapter.”

The new CEO search process is underway. In light of this transition, AGC Biologics announced that Tadashi Murano, President of the AGC Life Science Company, will serve as interim CEO. Murano brings several decades of experience in global leadership roles within AGC Inc. across various business entities.

For more information on AGC Biologics, visit www.agcbio.com.

AGC Biologics is a leading global biopharmaceutical CDMO committed to delivering the highest standard of service, working side-by-side with clients and partners every step of the way. The company specializes in the development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. With a global network spanning the U.S., Europe, and Asia, AGC Biologics operates cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan. Employing more than 2,500 team members worldwide, the company focuses on continuous innovation to solve complex challenges, including specialization in fast-track projects and rare diseases.

To learn more, visit www.agcbio.com.

View source version on newsdirect.com: https://newsdirect.com/news/agc-biologics-and-chief-executive-officer-patricio-massera-announce-plans-for-him-to-step-down-501638257